Affordable Access

Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide

Authors
Journal
Journal of Neurology Neurosurgery & Psychiatry
0022-3050
Publisher
BMJ
Publication Date
Keywords
  • Short Report
Disciplines
  • Medicine

Abstract

Three patients with Parkinson's disease are described who developed pericardial, retroperitoneal, and pleural fibrosis associated with pergolide treatment. Surgical intervention was required in all three cases, either to reach a tissue diagnosis or for potentially life threatening complications. Symptoms emerged on average 2years after the institution of treatment, and were sufficiently non-specific to cause significant delays in diagnosis in all cases. The erythrocyte sedimentation rate (ESR) was raised in the two patients in whom it was measured. Serosal fibrosis is a rarely reported adverse effect of pergolide treatment, although it is well described with other dopamine agonists. We suggest that patients with Parkinson's disease who receive pergolide treatment should be regularly monitored for the development of such complications.



There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Pericardial, retroperitoneal, and pleural fibrosis...

on Journal of Neurology Neurosurg... January 1999

Pergolide-induced retroperitoneal fibrosis.

on International journal of clini... 2000

Methysergide-induced retroperitoneal fibrosis and...

on Internal medicine journal May 2004
More articles like this..